Prevention of portal vein thrombosis with anticoagulant therapy in patients with hepatic cirrhosis

ISRCTN ISRCTN32383354
DOI https://doi.org/10.1186/ISRCTN32383354
EudraCT/CTIS number 2007-007890-22
Secondary identifying numbers EudraCT Number: 2007-007890-22
Submission date
13/02/2012
Registration date
21/02/2012
Last edited
18/10/2017
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Digestive System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Portal vein thrombosis (PVT) is blockage or narrowing of the portal vein (which brings blood from the intestines to the liver) by a blood clot. It is a frequent event in patients with advanced cirrhosis (scarring of the liver). When it occurs anticoagulant treatment improves the course of the disease. The aim of this study is to find out whether PVT can be prevented with the drug enoxaparin.

Who can participate?
Patients aged 18 and over with cirrhosis

What does the study involve?
Participants are randomly allocated to either be treated with enoxaparin daily for 1 year or to receive no treatment. The two groups are compared to see whether enoxaparin prevents PVT.

What are the possible benefits and risks of participating?
Enoxaparin is safe and effective at treating established PVT. Therefore, the benefits far outweigh the risks.

Where is the study run from?
University Hospital of Modena (Italy)

When is the study starting and how long is it expected to run for?
April 2008 to August 2012

Who is funding the study?
University Hospital of Modena (Italy)

Who is the main contact?
Prof. Erica Villa
erica.villa@unimore.it

Contact information

Prof Erica Villa
Scientific

Via del Pozzo 71
Modena
41124
Italy

Email erica.villa@unimore.it

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typePrevention
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titlePrevention of portal vein thrombosis with anticoagulant therapy in patients with hepatic cirrhosis: a randomised controlled trial
Study objectivesPortal vein thrombosis (PVT) in patients with advanced cirrhosis may be prevented by prophylactic doses of enoxaparin.
Ethics approval(s)Ethics Committee Modena, 15/10/2007, ref: AOMODEN_*IV_2007_006
Health condition(s) or problem(s) studiedAdvanced stage cirrhosis
InterventionExperimental arm: Enoxaparin (Sanofi Aventis, Milan) subcutaneously at a dose of 4000 IU/day for 1 year.
Control arm: No treatment.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Enoxaparin
Primary outcome measurePrevention of portal or mesenteric vein thrombosis
Secondary outcome measures1. Occurrence or recurrence of liver decompensation, defined as development of ascites, PSE, portal hypertensive bleeding, spontaneous bacterial peritonitis, or systemic infection
2. Overall and transplant-free survival
Overall study start date01/04/2008
Completion date30/08/2012

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants66
Key inclusion criteria1. Age ≥18 years old
2. Cirrhosis of any etiology
3. Child-Pugh score between B7 to C10
3. No evidence of PVT or spleno-mesenteric thrombosis by ultrasound evaluation and angio-CT, hepatic, renal and coagulative evaluation
Key exclusion criteria1. Age > 75 years
2. Ascites or porto-systemic encephalopathy (PSE) at time of enrollment or during the previous 3 months
3. History of gastrointestinal bleeding, hepatocellular carcinoma, other intra/extra-hepatic cancers, or thromboembolic disease
4. Ongoing anticoagulation, antiaggregation, or antiphospholipid antibody treatmen
5. Pregnancy or breastfeeding
6. F2 varices with red whale marks or F3 varices unless ligated
7. Platelet count < 10.000/mmc
8. Evidence of paroxysmal nocturnal hemoglobinuria (based on CD 55-CD 59 flow-cytometry); or
9. Human immunodeficiency virus (HIV) infection
Date of first enrolment01/04/2008
Date of final enrolment30/08/2012

Locations

Countries of recruitment

  • Italy

Study participating centre

University Hospital of Modena (Azienda Ospedaliero-Universitaria di Modena) (Italy)
Modena
41124
Italy

Sponsor information

University Hospital of Modena (Azienda Ospedaliero-Universitaria di Modena) (Italy)
Hospital/treatment centre

Funders

Funder type

Hospital/treatment centre

University Hospital of Modena (Azienda Ospedaliero-Universitaria di Modena) (Italy)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/11/2012 Yes No

Editorial Notes

18/10/2017: Plain English summary added.